Pay in 4 interest-free payments of $18.75 Learn more
Ships within 48 hours · Estimated delivery Jul 28 - Aug 2
also known as PCI-32765
N[C@H]1CN(CCC1)[C@@H]1CC2=CC=CC=C2[C@H]1OC1=CC=C(C=C1Cl)C#N
Feltell RE
InChiKey: AMBQHHVBBHTQBF-CBQOGAMZSA-N
Nitazoxanide: a first-in-class broad-spectrum antiviral agent
Empagliflozin - CAS# 864070-44-0 Catalog No.:M10131-10 also known as PCI-32765Empagliflozin, also known as BI10773 (trade name Jardiance), is drug approved for the treatment of type 2 diabetes in adults in 2014. It was developed by Boehringer Ingelheim and Eli Lilly and Company. Empagliflozin is an inhibitor of the sodium glucose co transporter 2 (SGLT 2), and causes sugar in the blood to be absorbed by the kidneys and eliminated in urine. Empagliflozin is an inhibitor of the sodium glucose co transporter 2 (SGLT 2), which is
US$ 29.00
US$ 1668.34
US$ 662.05
US$ 10720.51